You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

VANTRELA ER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Vantrela Er patents expire, and what generic alternatives are available?

Vantrela Er is a drug marketed by Teva Branded Pharm and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-three patent family members in thirteen countries.

The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vantrela Er

A generic version of VANTRELA ER was approved as hydrocodone bitartrate by ALVOGEN on January 21st, 2020.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VANTRELA ER?
  • What are the global sales for VANTRELA ER?
  • What is Average Wholesale Price for VANTRELA ER?
Summary for VANTRELA ER
International Patents:33
US Patents:3
Applicants:1
NDAs:1
DailyMed Link:VANTRELA ER at DailyMed
Drug patent expirations by year for VANTRELA ER

US Patents and Regulatory Information for VANTRELA ER

VANTRELA ER is protected by three US patents.

Patents protecting VANTRELA ER

Abuse resistant drug formulation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Abuse resistant drug formulation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Abuse resistant drug formulation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-001 Jan 17, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-003 Jan 17, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-002 Jan 17, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-004 Jan 17, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-003 Jan 17, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Branded Pharm VANTRELA ER hydrocodone bitartrate TABLET, EXTENDED RELEASE;ORAL 207975-005 Jan 17, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VANTRELA ER

When does loss-of-exclusivity occur for VANTRELA ER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Patent: 63172
Patent: PREPARATION MEDICAMENTEUSE EMPECHANT L'UTILISATION ABUSIVE (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 99142
Patent: FORMULATION MEDICAMENTEUSE CONTRE L'ABUS (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 15005
Estimated Expiration: ⤷  Sign Up

Patent: 16598
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 73795
Estimated Expiration: ⤷  Sign Up

Patent: 00593
Estimated Expiration: ⤷  Sign Up

Patent: 92341
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 73795
Patent: PRÉPARATION MÉDICAMENTEUSE EMPÊCHANT L'UTILISATION ABUSIVE (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 00593
Patent: FORMULATION MÉDICAMENTEUSE CONTRE L'ABUS (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 92341
Patent: Préparation médicamenteuse empêchant l'utilisation abusive (Abuse resistant drug formulation)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 34775
Patent: 抗濫用藥物製劑 (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷  Sign Up

Patent: 93567
Patent: 抗濫用藥物配方 (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 27128
Estimated Expiration: ⤷  Sign Up

Patent: 32012
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 57032
Estimated Expiration: ⤷  Sign Up

Patent: 30572
Estimated Expiration: ⤷  Sign Up

Patent: 11504455
Estimated Expiration: ⤷  Sign Up

Patent: 11517654
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 6861
Patent: FORMULACION DE FARMACO RESISTENTE AL ABUSO. (ABUSE RESISTANT DRUG FORMULATION.)
Estimated Expiration: ⤷  Sign Up

Patent: 09002757
Patent: FORMULACION DE FARMACO RESISTENTE AL ABUSO. (ABUSE RESISTANT DRUG FORMULATION.)
Estimated Expiration: ⤷  Sign Up

Patent: 10002780
Patent: FORMULACION DE FARMACO RESISTENTE AL ABUSO. (ABUSE RESISTANT DRUG FORMULATION.)
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 73795
Estimated Expiration: ⤷  Sign Up

Patent: 00593
Estimated Expiration: ⤷  Sign Up

Patent: 92341
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 73795
Estimated Expiration: ⤷  Sign Up

Patent: 92341
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 73795
Estimated Expiration: ⤷  Sign Up

Patent: 92341
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 52033
Estimated Expiration: ⤷  Sign Up

Patent: 43802
Estimated Expiration: ⤷  Sign Up

Patent: 11794
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VANTRELA ER around the world.

Country Patent Number Title Estimated Expiration
Denmark 2692341 ⤷  Sign Up
Cyprus 1116598 ⤷  Sign Up
Denmark 2200593 ⤷  Sign Up
Spain 2611794 ⤷  Sign Up
Hungary E027128 ⤷  Sign Up
Canada 2699142 FORMULATION MEDICAMENTEUSE CONTRE L'ABUS (ABUSE RESISTANT DRUG FORMULATION) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.